Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations.

Biochemical pharmacology - 1 Apr 2008

Mackenzie Gerardo G, Adamo Ana M, Decker Noah P, Oteiza Patricia I

Abstract excerpt

Due to long-term toxicity of current Hodgkin's lymphoma (HL) treatment, the present challenge is to find new therapies that specifically target deregulated signaling cascades, including NF-kappaB, which are involved in Hodgkin (H) and Reed-Sternberg (RS) cell proliferation and resistance to apoptosis. We previously presented evidence that dimeric procyanidin B2 (B2) can interact with NF-kappaB proteins inhibiting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catechin
Share to Dimerization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Hodgkin Disease

Share to I-kappa B Kinase

Share to Jurkat Cells

Share to NF-kappa B

Share to Proanthocyanidins

Source

Identifiers

PMID: 18275936
DOI: 10.1016/j.bcp.2007.12.013

Genes

STAT3
XIAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations.PMID 18275936Read ↗

Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.Semantic proximity Read ↗

Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cellsSemantic proximity Read ↗

NF-κB deregulation in Hodgkin lymphoma.Semantic proximity Read ↗

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.Semantic proximity Read ↗

Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells.Semantic proximity Read ↗

NF-&#954;B in Human Disease: Current Inhibitors and Prospects for De Novo Structure Based Design of InhibitorsSemantic proximity Read ↗

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLLSemantic proximity Read ↗

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSemantic proximity Read ↗

High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cellsSemantic proximity Read ↗

IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.Semantic proximity Read ↗

NF-κB as a therapeutic target in chronic lymphocytic leukemiaSemantic proximity Read ↗

Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.